Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
ex scientia Ltd
ex scientia Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Ingredients
Transatlantic partnership to screen 15,000 drugs for COVID-19 treatments
Exscientia has announced a joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research
Research & Development
Exscientia initiates sixth AI drug discovery partnership
Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Analysis
Exscientia appoints Georgy Egorov as Chief Financial Officer
Research & Development
Elsevier welcomes six biotech and pharma start-ups to The Hive
Start-ups working on a range of technologies and discoveries — from AI to immunotherapy — receive complimentary access to Elsevier's information solutions to accelerate innovation
Recruitment
Exscientia appoints Alex Snow as Deputy Chairman
Digital
Exscientia enters drug discovery collaboration with GSK
Exscientia, an innovative artificial intelligence driven drug discovery company, has entered into a strategic drug discovery collaboration with GlaxoSmithKline
Research & Development
Collaboration in bispecific-small-molecule drugs for metabolic disease
€250m agreement between Exscientia and Sanofi is for multiple-product development and licence option
Subscribe now